**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 68205

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis**

Maslennikov R *et al*. Gut dysbiosis and SIBO in cirrhosis

Roman Maslennikov, Vladimir Ivashkin, Irina Efremova, Elena Poluektova, Anna Kudryavtseva, George Krasnov

**Roman Maslennikov, Vladimir Ivashkin, Irina Efremova, Elena Poluektova,** Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Moscow 119435, Russia

**Roman Maslennikov, Vladimir Ivashkin, Elena Poluektova, Anna Kudryavtseva,** Scientific Community for Human Microbiome Research, Moscow 119435, Russia

**Roman Maslennikov,** Department of Internal Medicine 1, Сonsultative and Diagnostic Center 2 of the Moscow City Health Department, Moscow 107564, Russia

**Anna Kudryavtseva, George Krasnov,** Laboratory of Postgenomic Research, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia

**Author contributions:** Ivashkin V contributed research idea; Ivashkin V and Maslennikov R contributed study design; all authors contributed research and data analysis; Kudryavtseva A performed gut microbiota sequencing; Krasnov G performed bioinfomatics analysis of gut microbiota sequencing data; Maslennikov R contributed draft writing; all authors contributed draft editing; Maslennikov R is the guarantor.

**Supported by** Biocodex Microbiota Foundation: National Research Grant Russia 2019.

**Corresponding author: Roman Maslennikov, MD, PhD, Assistant Professor, Professor,** Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, Pogodinskaya str., 1, bld. 1, Moscow 119435, Russia. mmmm00@yandex.ru

**Received:** May 15, 2021

**Revised:** June 29, 2021

**Accepted: February 9, 2022**

**Published online:**

**Abstract**

BACKGROUND

Gut dysbiosis and small intestinal bacterial overgrowth (SIBO) are commonly observed in patients with cirrhosis. Despite the substantial number of articles describing the relations between disorders of gut microbiota and various manifestations of cirrhosis, dysbiosis and SIBO were always studied separately.

AIM

To study the relationship of gut dysbiosis and SIBO in cirrhosis.

METHODS

This observational study included 47 in-patients with cirrhosis. Stool microbiome was assessed using 16S rRNA gene sequencing. SIBO was assessed using the lactulose hydrogen breath test.

RESULTS

SIBO was found in 24/47 (51.1%) patients. Patients with SIBO had a higher abundance of Firmicutes (*P* = 0.017) and Fusobacteria (*P* = 0.011), and a lower abundance of Bacteroidetes (*P* = 0.013) than patients without SIBO. This increase in the abundance of Firmicutes occurred mainly due to an increase in the abundance of bacteria from the genus *Blautia* (*P* = 0.020) of the *Lachnospiraceae* family (*P* = 0.047), while the abundance of other major families of this phylum [*Ruminococcaceae* (*P* = 0.856), *Peptostreptococcaceae* (*P* = 0.066), *Clostridiaceae* (*P* = 0.463), *Eubacteriaceae* (*P* = 0.463), *Lactobacillaceae* (*P* = 0.413), and *Veillonellaceae* (*P* = 0.632)] did not differ significantly between the patients with and without SIBO. Reduced level of Bacteroidetes in samples from patients with SIBO was a result of the decrease in bacterial numbers from all the major families of this phylum [*Bacteroidaceae* (*P* = 0.014), *Porphyromonadaceae* (*P* = 0.002), and *Rikenellaceae* (*P* = 0.047)], with the exception of *Prevotellaceae* (*P* = 0.941). There were no significant differences in the abundance of taxa that were the main biomarkers of cirrhosis-associated gut dysbiosis [Proteobacteria (*P* = 0.790), Bacilli (*P* = 0.573), *Enterobacteriaceae* (*P* = 0.632), *Streptococcaceae* (*P* = 0.170), *Staphylococcaceae* (*P* = 0.450), and *Enterococcaceae* (*P* = 0.873)] between patients with and without SIBO.

CONCLUSION

Despite the differences observed in the gut microbiome between patients with and without SIBO, gut dysbiosis and SIBO are most likely independent disorders of gut microbiota in cirrhosis.

**Key Words:** Dysbiosis; Gut-liver axis; Microbiome; Small intestinal bacterial overgrowth; Cirrhosis; Microbiota

Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Kudryavtseva A, Krasnov G. Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis. *World J Gastroenterol* 2022; In press

**Core Tip:** Patients with small intestinal bacterial overgrowth (SIBO) had a higher abundance of Firmicutes and Fusobacteria, and a lower abundance of Bacteroidetes than patients without SIBO. This increase in the abundance of Firmicutes occurred mainly due to an increase in the abundance of bacteria from the genus Blautia of the Lachnospiraceae family. There were no significant differences in the abundance of taxa that were the main biomarkers of cirrhosis-associated gut dysbiosis.

**INTRODUCTION**

Cirrhosis is one of the most serious problems in hepatology and is not only a disease of the liver, but it also affects other organs. The damage that occurs in these other organs can contribute to further progression of cirrhosis, forming a vicious circle. The examples of such organs are the gut and the community of microorganisms that reside within it (the gut microbiota). Two forms of disorders of gut microbiota have been described in cirrhosis: changes in its composition[1-5] (gut dysbiosis[6-10]) and an increase of bacterial number in the small intestine (small intestinal bacterial overgrowth, SIBO)[11-14]. It is believed that these disorders, in combination with increased intestinal permeability, lead to increased penetration of bacteria and their components into the intestinal wall, mesenteric lymph nodes, ascitic fluid, and portal and systemic bloodstreams[15]. This, in turn, leads to systemic inflammation, vasodilation, compensatory fluid retention, and worsening portal hypertension[16,17].

Despite the substantial number of articles describing the relations between disorders of gut microbiota and various manifestations of cirrhosis, dysbiosis and SIBO were always studied separately. Our research aims to study the relationship of gut dysbiosis and SIBO in cirrhosis.

**MATERIALS AND METHODS**

***Patients***

In this observational study, 95 consecutive patients with cirrhosis were admitted to the Department of Hepatology of Clinic for Internal Diseases, Gastroenterology and Hepatology at Sechenov University (Moscow, Russia) and screened for inclusion. The study procedures were explained to potential participants, and written informed consent was obtained before enrollment. The present study was approved by the Ethics Committee of Sechenov University.

The inclusion criteria were as follows: diagnosis of cirrhosis verified by histology or clinical, biochemical, and ultrasound findings; and age between 18 and 70 years. The exclusion criteria were as follows: use of lactulose, lactitol, or other prebiotics, probiotics, antibiotics, or metformin in the past 6 wk; alcohol consumption in the past 6 wk; or inflammatory bowel disease, cancer, or any other serious disease. We used these criteria to exclude the influence of these factors on the composition of the gut microbiota. Of the original 95 patients screened for inclusion, 47 were enrolled in the study while 48 were excluded (Figure 1).

***SIBO assessment***

The participants of this study were 47 in-patients who were diagnosed with cirrhosis at admission. The morning after admission, SIBO was assessed using a lactulose hydrogen breath test (Gastrolyzer, Bedfont, The United Kingdom), following the manufacturer’s instructions and in accordance with the North American Consensus[18]. Participants were considered to have SIBO if breath hydrogen concentration increased by at least 20 ppm above the baseline value within 90 min[18].

***Gut microbiome analysis***

The morning after admission, a stool sample was taken into a sterile disposable container and immediately frozen at -80 °C[19].

DNA from the stool was isolated using the MagNa Pure Compact Nucleic Acid Isolation Kit I (Roche, Basel, Switzerland) according to the manufacturer’s instructions. Libraries for sequencing were prepared by two rounds of polymerase chain reaction (PCR) amplification. In the first round, specific primers for the v3-v4 region of the 16S ribosomal RNA gene were used: 16S-F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG and 16S-R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC.

After amplification, the PCR product was purified using AMPure XP magnetic beads (Beckman Coulter, Brea, CA, United States). Then, a second round of PCR was performed to attach specific adapters and enable multiplexing of the samples. To begin, 5 μL of the first PCR product was added to the reaction after ball cleaning with primers containing Illumina indices (Nextera XT Index v2 Primers; San Diego, CA, United States) and adapter sequences as well as 2× KAPA HiFi HotStart ReadyMix. The amplification products were also purified using AMPure XP beads (Beckman Coulter). The concentrations of the prepared libraries were then measured using a Qubit 2.0 fluorimeter (London, United Kingdom) and quantitative PCR. The quality of the libraries was assessed using the Agilent 2100 Bioanalyzer (Santa Clara, CA, United States). The libraries were mixed in equal proportions and diluted to the required concentration to be run on a MiSeq (Illumina) device. Pair-end readings of 300 + 300 nucleotides were obtained. Reads were trimmed from the 3’-tail with Trimmomatic (Illumina) and then merged into a single amplicon with the MeFiT tool[20,21]. We did not perform operational taxonomic unit picking; instead, we classified amplicon sequences with the Ribosomal Database Project (RDP) classifier and RDP database[22].

***Statistical analysis***

Statistical analysis was performed with STATISTICA 10 (StatSoft Inc., Tulsa, OK, United States). The data are presented as medians (interquartile ranges). The abundance of taxa of the gut microbiome is presented as a percentage. Differences between continuous variables were assessed with the Mann-Whitney test. Fisher’s exact test was used to assess the differences between categorical variables. *P* values ≤ 0.05 were considered as statistically significant.

**RESULTS**

Out of the 47 participants in our study, the results from the lactulose hydrogen breath test revealed that 24 (51.1%) of patients met the criteria for SIBO. No significant differences in etiology (Figure 2), demographics, drugs used before inclusion, and the main manifestations of cirrhosis were observed between patients with and without SIBO, other than the value of C-reactive protein, which was higher in patients with SIBO. Patients with SIBO also displayed a trend toward having a larger spleen and higher incidence of ascites (Table 1).

In terms of phyla, samples from patients with SIBO revealed a higher abundance of Firmicutes and Fusobacteria, and lower abundance of Bacteroidetes compared to those from patients without SIBO. There were no significant differences in the numbers of Proteobacteria and Actinobacteria as well as the main Firmicutes classes (Clostridia, Bacilli and Negativicutes, Table 2).

Our results reveal that the increase in the abundance of Firmicutes observed in patients with SIBO occurs mainly due to a larger population of bacterial species from the *Lachnospiraceae* family. The number of bacteria from the other major families of this phylum does not differ significantly between the samples taken from the two groups of patients (Table 3). After the exclusion of *Lachnospiraceae* from Firmicutes, the difference in the abundance of bacteria under this phylum was no longer significant [39.8 (32.3-53.3) *vs* 42.6 (25.1-54.3); *P* = 0.773].

The reduced population of Bacteroidetes in patients with SIBO results from a reduction in all major families of this phylum, with the exception of *Prevotellaceae*. Although there was no significant difference in the overall levels of Proteobacteria between the samples from the two patient groups, differences were detected in the minor families of the phylum. Specifically, samples from patients with SIBO revealed that the proportion of *Pasteurellaceae* and *Moraxellaceae* were higher, and *Desulfovibrionaceae* was lower, compared to those from patients without SIBO. Similarly, there was also no significant difference in the overall levels of bacteria in the Actinobacteria phylum, but the proportion of bacteria from the *Actinomycetaceae* and *Micrococcaceae* minor families were higher in the samples taken from patients with SIBO than in samples from patients without (Table 3).

At the genus level, analysis of samples from patients with SIBO revealed increased the abundance of *Blautia*, *Fusicatenibacter*, *Acinetobacter*, *Oribacterium*, and *Haemophilus* bacteria compared to the samples of patients without SIBO. In contrast, *Bacteroides*, *Oscillibacter*, *Alistipes*, *Parabacteroides*, *Barnesiella*, and *Intestinimonas* levels were lower (Table 4).

Further analysis demonstrated that *Brautia* was the main contributor to the increase in the abundances of the *Lachnospiraceae* family and the Firmicutes phylum in patients with SIBO. After subtracting the contribution of these bacteria, the statistical differences between the patient groups were no longer significant [*Lachnospiraceae*: 28.6 (19.6-35.0) *vs* 23.2 (10.7-33.2), *P* = 0.177; Firmicutes: 74.0 (62.2-79.5) *vs* 65.7 (55.9-78.6); *P* = 0.425].

The Firmicutes/Bacteroides ratio was significantly higher in patients with SIBO than in patients without SIBO, while the modified dysbiosis ratio that determines the prognosis in cirrhosis[10] did not differ significantly between the two groups of patients (Figure 3).

**DISCUSSION**

We detect SIBO in half of the patients with cirrhosis, which is consistent with the data of previous studies[13]. SIBO is thought be caused by a slowdown in the motility of the small intestine, use of proton pump inhibitors, exocrine pancreatic insufficiency, immune and other disorders[23,24]. Furthermore, an association between delayed orocecal transit and SIBO has been reported in patients with cirrhosis[25]. Despite the presence of immune disorders[26], there are no studies on the association of them with the development of SIBO in cirrhosis. There was no difference in the frequency of using proton pump inhibitors between the patients with and without SIBO in our study.

Cirrhosis-associated gut dysbiosis is represented by an increase in the abundance of Proteobactria that produce active endoctoxin[1-5], and the facultative anaerobic bacteria Bacilli[4,6-8] that is capable of bacterial translocation[27]. This is accompanied by the decrease in the levels of beneficial bacteria from the major families under the Clostridia class[4,7,8,10]. Since the number of Clostridia and Bacilli bacteria can change in opposite directions, the abundance of Firmicutes, which include Clostridia and Bacilli, has been demonstrated to be either increased[9] or decreased[5] in cirrhosis. The change in levels of Bacteriodetes in cirrhosis has been reported to decrease[1,9], increase[2], not change[10], and be increased in compensated cirrhosis, while reduced to normal in decompensated cirrhosis[7].

The mechanisms that lead to gut dysbiosis in cirrhosis are not clear; it is suggested that they may be similar to those for SIBO. If SIBO and gut dysbiosis result from the same factors, it would be logical to assume that dysbiosis is more pronounced in patients with SIBO. However, the abundance of the main biomarkers of cirrhosis-associated dysbiosis (Proteobacteria, Bacilli and Clostridia) was not significantly different between patients with and without SIBO in our study. Moreover, the abundance of *Lachnospiraceae*, a decrease in which is also one of the biomarkers of cirrhosis-associated dysbiosis[6-8,10], on the contrary, was significantly higher in SIBO.

The gut microbiome has been evaluated depending on the presence of SIBO in patients who do not have cirrhosis in a small number of studies. It was shown that the composition of the small intestine[28,29] and fecal[30] microbiome does not depend significantly on the presence of SIBO. However, among patients with diarrheal variant of irritable bowel syndrome, the abundance of *Prevotella* were higher, while the abundance of *Bacteroides* were reduced in persons with SIBO compared with persons without SIBO[31]. Another study revealed that Firmicutes was increased in fecal microbiota of patients with SIBO[32]. Our research also showed an increase in the abundance of Firmicutes and a decrease in the abundance of *Bacteroides* but without a significant change in the abundance of *Prevotella* in fecal microbiota of patients with SIBO. Thus, changes in the gut microbiome of SIBO patients with cirrhosis are partly consistent with changes in it in SIBO patients with other diseases and do not coincide with the changes that are characteristic of cirrhosis-associated dysbiosis.

An increase in Firmicutes/Bacteroides ratio which was observed in our study in patients with SIBO is reported in patients with a significant slowdown in orosecal transit in cirrhosis[9]. Nevertheless, there were no differences in the abundance of Proteobacteria and Bacilli between cirrhotic patients with normal and delayed orocecal in that study. It can therefore be assumed that the slowing down of orocecal transit is a main factor in the development of SIBO, but it has a minimal effect on the development of cirrhosis-associated gut dysbiosis.

In our study, bacterial species that mainly increase in patients with SIBO belong to the *Blautia* genus. These bacteria have the ability to convert primary bile acids into secondary bile acids[33], for example, chenodeoxycholic acid to lithocholic acid. The ratio of lithocholic to chenodeoxycholic acid in feces strongly correlates with the content of *Blautia* in the gut microbiome of cirrhosis patients[8]. Furthermore, an increase in the content of bile acids in the feces is accompanied by an increase in the abundance of *Blautia* in persons on a cholerectic diet[34].

The changes in bile metabolism may explain the differences in the gut microbiome of cirrhosis patients with SIBO. The increase in the number of bacteria leads to the increased deconjugation of primary bile acids in the small intestine in patients with SIBO[35]. As deconjugated primary bile acids have a lower affinity for the proteins that carry them through the epithelium of the terminal ileum[36], more of these acids enter the large intestine. These bile acids may be a growth factor for *Blautia* and similar bacteria. The reduction in the abundance of Bacteroidetes may be the result of suppression their growth by bile acids or due to antagonism with *Blautia*. A larger study examining the amount and composition of bile acids in feces, the time of orocecal transit, the gut microbiome, and SIBO in cirrhosis should be performed to test this hypothesis.

The strength of our study is represented by the facts that it is the first that assesses the relationship between SIBO and gut dysbiosis in cirrhosis, as well as that we suggested the mechanism of development of changes in the gut microbiota in cirrhosis patients with SIBO and the idea for the next studies that can confirm or refute this hypothesis.

The limitation of our study is its small size, but this did not prevent significant results from being obtained.

**CONCLUSION**

In conclusion, we showed that despite the difference in the gut microbiome between patients with and without SIBO, gut dysbiosis and SIBO are most likely relatively independent forms of disorders of the gut microbiota in cirrhosis.

**ARTICLE HIGHLIGHTS**

***Research background***

Gut dysbiosis and small intestinal bacterial overgrowth (SIBO) are commonly observed in patients with cirrhosis.

***Research motivation***

Despite the substantial number of articles describing the relations between disorders of gut microbiota and various manifestations of cirrhosis, dysbiosis and SIBO were always studied separately.

***Research objectives***

To study the relationship of gut dysbiosis and SIBO in cirrhosis.

***Research methods***

This observational study included 47 in-patients with cirrhosis. Stool microbiome was assessed using 16S rRNA gene sequencing. SIBO was assessed using the lactulose hydrogen breath test.

***Research results***

Patients with SIBO had a higher abundance of Firmicutes and Fusobacteria, and a lower abundance of Bacteroidetes than patients without SIBO. This increase in the abundance of Firmicutes occurred mainly due to an increase in the abundance of bacteria from the genus *Blautia* of the *Lachnospiraceae* family, while the abundance of other major families of this phylum did not differ significantly between the patients with and without SIBO. There were no significant differences in the abundance of taxa that were the main biomarkers of cirrhosis-associated gut dysbiosis  between patients with and without SIBO.

***Research conclusions***

Despite the differences observed in the gut microbiome between patients with and without SIBO, gut dysbiosis and SIBO are most likely independent disorders of gut microbiota in cirrhosis.

***Research perspectives***

Research perspectives are to study the mechanisms of development of  SIBO and gut dysbiosis in patients with cirrhosis.

**ACKNOWLEDGEMENTS**

The authors are grateful to the staff of the Department of Hepatology: Zharkova M, Lapshin A, Ondos S, Fedosina E, Tkachenko P, Tikhonov I, and others.

**REFERENCES**

1 **Jin M**, Kalainy S, Baskota N, Chiang D, Deehan EC, McDougall C, Tandon P, Martínez I, Cervera C, Walter J, Abraldes JG. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. *Liver Int* 2019; **39**: 1437-1447 [PMID: 30919578 DOI: 10.1111/liv.14106]

2 **Zeng Y**, Chen S, Fu Y, Wu W, Chen T, Chen J, Yang B, Ou Q. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. *J Viral Hepat* 2020; **27**: 143-155 [PMID: 31600845 DOI: 10.1111/jvh.13216]

3 **Kajihara M**, Koido S, Kanai T, Ito Z, Matsumoto Y, Takakura K, Saruta M, Kato K, Odamaki T, Xiao JZ, Sato N, Ohkusa T. Characterisation of blood microbiota in patients with liver cirrhosis. *Eur J Gastroenterol Hepatol* 2019; **31**: 1577-1583 [PMID: 31441799 DOI: 10.1097/MEG.0000000000001494]

4 **Chen Z**, Xie Y, Zhou F, Zhang B, Wu J, Yang L, Xu S, Stedtfeld R, Chen Q, Liu J, Zhang X, Xu H, Ren J. Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease. *Front Microbiol* 2020; **11**: 383 [PMID: 32265857 DOI: 10.3389/fmicb.2020.00383]

5 **Zheng R**, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. *Cancer Med* 2020; **9**: 4232-4250 [PMID: 32281295 DOI: 10.1002/cam4.3045]

6 **Lapidot Y**, Amir A, Nosenko R, Uzan-Yulzari A, Veitsman E, Cohen-Ezra O, Davidov Y, Weiss P, Bradichevski T, Segev S, Koren O, Safran M, Ben-Ari Z. Alterations in the Gut Microbiome in the Progression of Cirrhosis to Hepatocellular Carcinoma. *mSystems* 2020; **5** [PMID: 32546668 DOI: 10.1128/mSystems.00153-20]

7 **Bajaj JS**, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. *J Hepatol* 2014; **60**: 940-947 [PMID: 24374295 DOI: 10.1016/j.jhep.2013.12.019]

8 **Kakiyama G**, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, White MB, Noble NA, Monteith P, Fuchs M, Thacker LR, Sikaroodi M, Bajaj JS. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. *J Hepatol* 2013; **58**: 949-955 [PMID: 23333527 DOI: 10.1016/j.jhep.2013.01.003]

9 **Liu Y**, Jin Y, Li J, Zhao L, Li Z, Xu J, Zhao F, Feng J, Chen H, Fang C, Shilpakar R, Wei Y. Small Bowel Transit and Altered Gut Microbiota in Patients With Liver Cirrhosis. *Front Physiol* 2018; **9**: 470 [PMID: 29780327 DOI: 10.3389/fphys.2018.00470]

10 **Maslennikov R**, Ivashkin V, Efremova I, Alieva A, Kashuh E, Tsvetaeva E, Poluektova E, Shirokova E, Ivashkin K. Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis. *World J Hepatol* 2021; **13**: 557-570 [PMID: 34131470 DOI: 10.4254/wjh.v13.i5.557]

11 **Ghosh G**, Jesudian AB. Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis. *J Clin Exp Hepatol* 2019; **9**: 257-267 [PMID: 31024208 DOI: 10.1016/j.jceh.2018.08.006]

12 **Shah A**, Shanahan E, Macdonald GA, Fletcher L, Ghasemi P, Morrison M, Jones M, Holtmann G. Systematic Review and Meta-Analysis: Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Liver Disease. *Semin Liver Dis* 2017; **37**: 388-400 [PMID: 29272899 DOI: 10.1055/s-0037-1608832]

13 **Maslennikov R**, Pavlov C, Ivashkin V. Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis. *Hepatol Int* 2018; **12**: 567-576 [PMID: 30284684 DOI: 10.1007/s12072-018-9898-2]

14 **Maslennikov R**, Pavlov C, Ivashkin V. Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis? *Turk J Gastroenterol* 2019; **30**: 964-975 [PMID: 31767551 DOI: 10.5152/tjg.2019.18551]

15 **Giannelli V**, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, Thalheimer U. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. *World J Gastroenterol* 2014; **20**: 16795-16810 [PMID: 25492994 DOI: 10.3748/wjg.v20.i45.16795]

16 **Simbrunner B**, Mandorfer M, Trauner M, Reiberger T. Gut-liver axis signaling in portal hypertension. *World J Gastroenterol* 2019; **25**: 5897-5917 [PMID: 31660028 DOI: 10.3748/wjg.v25.i39.5897]

17 **Ponziani FR**, Zocco MA, Cerrito L, Gasbarrini A, Pompili M. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. *Expert Rev Gastroenterol Hepatol* 2018; **12**: 641-656 [PMID: 29806487 DOI: 10.1080/17474124.2018.1481747]

18 **Rezaie A**, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. *Am J Gastroenterol* 2017; **112**: 775-784 [PMID: 28323273 DOI: 10.1038/ajg.2017.46]

19 **Fouhy F**, Deane J, Rea MC, O'Sullivan Ó, Ross RP, O'Callaghan G, Plant BJ, Stanton C. The effects of freezing on faecal microbiota as determined using MiSeq sequencing and culture-based investigations. *PLoS One* 2015; **10**: e0119355 [PMID: 25748176 DOI: 10.1371/journal.pone.0119355]

20 **Bolger AM**, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014; **30**: 2114-2120 [PMID: 24695404 DOI: 10.1093/bioinformatics/btu170]

21 **Parikh HI**, Koparde VN, Bradley SP, Buck GA, Sheth NU. MeFiT: merging and filtering tool for illumina paired-end reads for 16S rRNA amplicon sequencing. *BMC Bioinformatics* 2016; **17**: 491 [PMID: 27905885 DOI: 10.1186/s12859-016-1358-1]

22 **Wang Q**, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol* 2007; **73**: 5261-5267 [PMID: 17586664 DOI: 10.1128/AEM.00062-07]

23 **Achufusi TGO**, Sharma A, Zamora EA, Manocha D. Small Intestinal Bacterial Overgrowth: Comprehensive Review of Diagnosis, Prevention, and Treatment Methods. *Cureus* 2020; **12**: e8860 [PMID: 32754400 DOI: 10.7759/cureus.8860]

24 **Bures J**, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, Vorisek V, Kopacova M. Small intestinal bacterial overgrowth syndrome. *World J Gastroenterol* 2010; **16**: 2978-2990 [PMID: 20572300 DOI: 10.3748/wjg.v16.i24.2978]

25 **Lunia MK**, Sharma BC, Sachdeva S. Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy. *Hepatol Int* 2013; **7**: 268-273 [PMID: 26201641 DOI: 10.1007/s12072-012-9360-9]

26 **Irvine KM**, Ratnasekera I, Powell EE, Hume DA. Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. *Front Immunol* 2019; **10**: 293 [PMID: 30873165 DOI: 10.3389/fimmu.2019.00293]

27 **Berg RD**, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. *Infect Immun* 1979; **23**: 403-411 [PMID: 154474 DOI: 10.1128/iai.23.2.403-411.1979]

28 **Saffouri GB**, Shields-Cutler RR, Chen J, Yang Y, Lekatz HR, Hale VL, Cho JM, Battaglioli EJ, Bhattarai Y, Thompson KJ, Kalari KK, Behera G, Berry JC, Peters SA, Patel R, Schuetz AN, Faith JJ, Camilleri M, Sonnenburg JL, Farrugia G, Swann JR, Grover M, Knights D, Kashyap PC. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. *Nat Commun* 2019; **10**: 2012 [PMID: 31043597 DOI: 10.1038/s41467-019-09964-7]

29 **Shin AS**, Gao X, Bohm M, Lin H, Gupta A, Nelson DE, Toh E, Teagarden S, Siwiec R, Dong Q, Wo JM. Characterization of Proximal Small Intestinal Microbiota in Patients With Suspected Small Intestinal Bacterial Overgrowth: A Cross-Sectional Study. *Clin Transl Gastroenterol* 2019; **10**: e00073 [PMID: 31464691 DOI: 10.14309/ctg.0000000000000073]

30 **Noh CK**, Lee KJ. Fecal Microbiota Alterations and Small Intestinal Bacterial Overgrowth in Functional Abdominal Bloating/Distention. *J Neurogastroenterol Motil* 2020; **26**: 539-549 [PMID: 32989189 DOI: 10.5056/jnm20080]

31 **Wu KQ**, Sun WJ, Li N, Chen YQ, Wei YL, Chen DF. Small intestinal bacterial overgrowth is associated with Diarrhea-predominant irritable bowel syndrome by increasing mainly *Prevotella* abundance. *Scand J Gastroenterol* 2019; **54**: 1419-1425 [PMID: 31765575 DOI: 10.1080/00365521.2019.1694067]

32 **Yang M**, Zhang L, Hong G, Li Y, Li G, Qian W, Xiong H, Bai T, Song J, Hou X. Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome. *J Gastroenterol Hepatol* 2020; **35**: 795-805 [PMID: 31674052 DOI: 10.1111/jgh.14910]

33 **Ridlon JM**, Devendran S, Alves JM, Doden H, Wolf PG, Pereira GV, Ly L, Volland A, Takei H, Nittono H, Murai T, Kurosawa T, Chlipala GE, Green SJ, Hernandez AG, Fields CJ, Wright CL, Kakiyama G, Cann I, Kashyap P, McCracken V, Gaskins HR. The '*in vivo* lifestyle' of bile acid 7α-dehydroxylating bacteria: comparative genomics, metatranscriptomic, and bile acid metabolomics analysis of a defined microbial community in gnotobiotic mice. *Gut Microbes* 2020; **11**: 381-404 [PMID: 31177942 DOI: 10.1080/19490976.2019.1618173]

34 **Ocvirk S**, Wilson AS, Posma JM, Li JV, Koller KR, Day GM, Flanagan CA, Otto JE, Sacco PE, Sacco FD, Sapp FR, Wilson AS, Newton K, Brouard F, DeLany JP, Behnning M, Appolonia CN, Soni D, Bhatti F, Methé B, Fitch A, Morris A, Gaskins HR, Kinross J, Nicholson JK, Thomas TK, O'Keefe SJD. A prospective cohort analysis of gut microbial co-metabolism in Alaska Native and rural African people at high and low risk of colorectal cancer. *Am J Clin Nutr* 2020; **111**: 406-419 [PMID: 31851298 DOI: 10.1093/ajcn/nqz301]

35 **Bala L**, Ghoshal UC, Ghoshal U, Tripathi P, Misra A, Gowda GA, Khetrapal CL. Malabsorption syndrome with and without small intestinal bacterial overgrowth: a study on upper-gut aspirate using 1H NMR spectroscopy. *Magn Reson Med* 2006; **56**: 738-744 [PMID: 16972311 DOI: 10.1002/mrm.21041]

36 **Trauner M**, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. *Physiol Rev* 2003; **83**: 633-671 [PMID: 12663868 DOI: 10.1152/physrev.00027.2002]

**Footnotes**

**Institutional review board statement:** The present study was approved by the Ethics Committee of Sechenov University.

**Informed consent statement:** The study procedures were explained to potential participants, and written informed consent was obtained before enrollment.

**Conflict-of-interest statement:** No conflicts of interest.

**Data sharing statement:** The data can be provided upon request to the corresponding author.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 15, 2021

**First decision:** June 27, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Russia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Almeida C, Li YL, Salvadori M **S-Editor:** Gao CC **L-Editor: P-Editor:**


**Figure Legends**



**Figure 1 CONSORT 2010 flow diagram.** SIBO: Small intestinal bacterial overgrowth.



**Figure 2 Etiology of cirrhosis in patients with and without small intestinal bacterial overgrowth.** SIBO: Small intestinal bacterial overgrowth.



**Figure 3 Complex indices of gut microbiome in patients with and without small intestinal bacterial overgrowth.** SIBO: Small intestinal bacterial overgrowth.

**Table 1 Descriptive statistics of patients with and without small intestinal bacterial overgrowth**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Patients with SIBO (*n* = 24)** | **Patients without SIBO (*n* = 23)** | ***P* value** |
| Age, yr | 50 (39-59) | 51 (37-58) | 0.949 |
| Male/female | 12/12 | 11/12 | 0.557 |
| Body mass index, kg/m2 | 25.0 (22.9-27.8) | 24.1 (22.3-26.1) | 0.302 |
| Red blood cells, 1012/L | 3.7 (3.3-4.2) | 4.0 (3.6-4.3) | 0.322 |
| White blood cells, 109/L | 3.6 (2.6-4.9) | 4.0 (3.2-5.6) | 0.437 |
| Platelets, 109/L | 78 (49-108) | 90 (59-115) | 0.229 |
| C-reactive protein, mg/L | 11.4 (1.6-17.1) | 2.1 (0.1-9.2) | 0.025 |
| Serum albumen, g/L | 35 (31-40) | 36 (31-41) | 0.617 |
| Serum total bilirubin, μmol/L | 36 (27-54) | 38 (23-64) | 0.848 |
| Prothrombin (Quick test), % | 57 (50-68) | 64 (53-70) | 0.233 |
| Ascites, *n* (%) | 17 (70.8) | 10 (43.4) | 0.054 |
| Esophageal varices, *n* (%) | 19 (79.2) | 19 (82.6) | 0.528 |
| Spleen length, cm | 16.2 (14.0-20.0) | 14.6 (13.3-16.2) | 0.080 |
| Portal vein diameter, mm | 13.0 (12.0-13.7) | 12.0 (11.0-13.5) | 0.263 |
| Overt hepatic encephalopathy, *n* (%) | 9 (37.5) | 8 (34.8) | 0.544 |
| Child-Pugh score | 8 (6-10) | 8 (6-9) | 0.551 |
| **Drugs used by patients within 6 mo prior to study enrollment** | | | |
| Proton pump inhibitors, *n* (%) | 9 (37.5) | 8 (34.8) | 0.544 |
| Beta blockers, *n* (%) | 5 (20.8) | 3 (13.0) | 0.375 |
| L-ornithine-L-aspartate, *n* (%) | 4 (16.7) | 4 (17.4) | 0.625 |
| Diuretics, *n* (%) | 13 (54.2) | 8 (34.8) | 0.149 |
| Ursodeoxycholic acid, *n* (%) | 4 (16.7) | 5 (21.7) | 0.471 |
| Glucocorticoids, *n* (%) | 2 (8.3) | 6 (26.1) | 0.109 |
| Antiviral drugs, *n* (%) | 7 (29.2) | 4 (17.4) | 0.273 |

SIBO: Small intestinal bacterial overgrowth.

**Table 2 Abundance of bacteria at the phylum and class levels in gut microbiome of patients with and without small intestinal bacterial overgrowth**

|  |  |  |  |
| --- | --- | --- | --- |
| **Taxon** | **Patients with SIBO (*n* = 24)** | **Patients without SIBO (*n* = 23)** | ***P* value** |
| **Phyla** | | | |
| *Firmicutes* | 90.2 (77.7-94.3) | 80.0 (67.5-87.2) | 0.017 |
| *Bacteroidetes* | 5.3 (1.5-7.7) | 6.8 (5.6-1.3) | 0.013 |
| *Proteobacteria* | 1.3 (0.2-3.0) | 1.7 (0.2-4.1) | 0.790 |
| *Actinobacteria* | 0.5 (0.3-1.6) | 0.8 (0.4-3.8) | 0.343 |
| *Fusobacteria* | 0.01 (0.00-0.03) | 0.00 (0.00-0.00) | 0.011 |
| **Main classes of *Firmicutes*** | | | |
| *Clostridia* | 77.9 (67.1-84.6) | 70.9 (61.6-83.1) | 0.151 |
| *Bacilli* | 2.4 (0.4-7.1) | 1.1 (0.4-7.3) | 0.573 |
| *Negativicutes* | 0.5 (0.2-0.8) | 0.4 (0.2-1.4) | 0.956 |

SIBO: Small intestinal bacterial overgrowth.

**Table 3 Abundance of bacteria at the family level in gut microbiome of patients with and without small intestinal bacterial overgrowth**

|  |  |  |  |
| --- | --- | --- | --- |
| **Family** | **Patients with SIBO (*n* = 24)** | **Patients without SIBO (*n* = 23)** | ***P* value** |
| **Families of *Clostridia*** | | | |
| *Lachnospiraceae* | 41.00 (29.71-55.82) | 31.30 (17.55-43.85) | 0.047 |
| *Ruminococcaceae* | 26.15 (13.79-35.50) | 21.41 (14.89-34.43) | 0.856 |
| *Peptostreptococcaceae* | 0.50 (0.18-2.72) | 0.17 (0.04-1.13) | 0.066 |
| *Clostridiaceae* | 0.30 (0.01-1.12) | 0.10 (0.01-0.47) | 0.463 |
| *Eubacteriaceae* | 0.00 (0.00-0.00) | 0.00 (0.00-0.01) | 0.463 |
| **Families of *Bacilli*** | | | |
| *Streptococcaceae* | 1.46 (0.29-6.03) | 0.41 (0.10-3.42) | 0.170 |
| *Lactobacillaceae* | 0.23 (0.03-0.56) | 0.10 (0.01-0.38) | 0.413 |
| *Staphylococcaceae* | 0.02 (0.01-0.03) | 0.01 (0.01-0.02) | 0.450 |
| *Enterococcaceae* | 0.01 (0.00-0.04) | 0.01 (0.00-0.23) | 0.873 |
| **Family of *Negativicutes*** | | | |
| *Veillonellaceae* | 0.43 (0.07-0.73) | 0.16 (0.05-1.15) | 0.632 |
| **Families of *Bacteroidetes*** | | | |
| *Bacteroidaceae* | 1.13 (0.35-3.19) | 3.77 (1.05-4.96) | 0.014 |
| *Prevotellaceae* | 0.56 (0.01-3.12) | 0.27 (0.04-3.07) | 0.941 |
| *Porphyromonadaceae* | 0.11 (0.02-0.29) | 0.40 (0.23-0.66) | 0.002 |
| *Rikenellaceae* | 0.07 (0.01-0.74) | 0.45 (0.06-1.35) | 0.047 |
| **Families of *Proteobacteria*** | | | |
| *Enterobacteriaceae* | 0.72 (0.02-2.13) | 1.51 (0.05-2.81) | 0.632 |
| *Moraxellaceae* | 0.04 (0.02-0.05) | 0.02 (0.01-0.04) | 0.014 |
| *Pasteurellaceae* | 0.01 (0.00-0.15) | 0.00 (0.00-0.01) | 0.025 |
| *Sutterellaceae* | 0.01 (0.00-0.06) | 0.02 (0.00-0.05) | 0.400 |
| *Desulfovibrionaceae* | 0.00 (0.00-0.01) | 0.01 (0.00-0.03) | 0.042 |
| **Families of *Actinobacteria*** | | | |
| *Bifidobacteriaceae* | 0.46 (0.14-1.50) | 0.65 (0.12-3.22) | 0.366 |
| *Coriobacteriaceae* | 0.09 (0.07-0.14) | 0.08 (0.04-0.20) | 0.790 |
| *Actinomycetaceae* | 0.02 (0.01-0.04) | 0.01 (0.00-0.03) | 0.039 |
| *Micrococcaceae* | 0.02 (0.01-0.06) | 0.01 (0.00-0.01) | 0.045 |

SIBO: Small intestinal bacterial overgrowth.

**Table 4 Abundance of bacteria at the genus level in gut microbiome of patients with and without small intestinal bacterial overgrowth**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Genus** | **Family** | **Patients with SIBO (*n* = 24)** | **Patients without SIBO (*n* = 23)** | ***P* value** |
| *Blautia* | *Lachnospiraceae* | 13.38 (6.78-20.52) | 6.99 (3.22-13.47) | 0.020 |
| *Faecalibacterium* | *Ruminococcaceae* | 8.64 (3.65-19.55) | 7.82 (3.02-12.74) | 0.516 |
| *Gemmiger* | *Ruminococcaceae* | 2.33 (0.95-4.69) | 1.65 (0.03-2.86) | 0.237 |
| *Ruminococcus* | *Ruminococcaceae* | 1.80 (0.01-3.51) | 0.58 (0.12-1.83) | 0.617 |
| *Roseburia* | *Lachnospiraceae* | 1.66 (0.51-4.20) | 0.92 (0.13-3.42) | 0.377 |
| *Streptococcus* | *Streptococcaceae* | 1.36 (0.22-5.78) | 0.37 (0.08-3.42) | 0.151 |
| *Dorea* | *Lachnospiraceae* | 1.18 (0.63-2.51) | 0.69 (0.42-1.35) | 0.099 |
| *Bacteroides* | *Bacteroidaceae* | 1.15 (0.34-3.04) | 3.59 (1.08-5.05) | 0.012 |
| *Fusicatenibacter* | *Lachnospiraceae* | 0.79 (0.27-1.06) | 0.13 (0.04-0.31) | 0.003 |
| *Prevotella* | *Prevotellaceae* | 0.43 (0.01-2.27) | 0.12 (0.01-2.19) | 0.856 |
| *Escherichia* | *Enterobacteriaceae* | 0.38 (0.01-1.64) | 0.28 (0.01-1.31) | 0.890 |
| *Bifidobacterium* | *Bifidobacteriaceae* | 0.32 (0.11-1.15) | 0.47 (0.07-2.39) | 0.413 |
| *Oscillibacter* | *Oscillospiraceae* | 0.07 (0.01-0.15) | 0.21 (0.09-0.38) | 0.025 |
| *Alistipes* | *Rikenellaceae* | 0.06 (0.01-0.52) | 0.41 (0.06-1.25) | 0.025 |
| *Anaerostipes* | *Lachnospiraceae* | 0.62 (0.06-0.50) | 0.49 (0.08-0.67) | 0.170 |
| *Parabacteroides* | *Porphyromonadaceae* | 0.03 (0.00-0.11) | 0.16 (0.05-0.29) | 0.009 |
| *Acinetobacter* | *Moraxellaceae* | 0.03 (0.02-0.05) | 0.02 (0.01-0.03) | 0.004 |
| *Akkermansia* | *Akkermansiaceae* | 0.01 (0.00-0.71) | 0.01 (0.00-1.33) | 0.983 |
| *Oribacterium* | *Lachnospiraceae* | 0.01 (0.00-0.02) | 0.00 (0.00-0.00) | 0.040 |
| *Barnesiella* | *Porphyromonadaceae* | 0.00 (0.00-0.03) | 0.03 (0.00-0.06) | 0.025 |
| *Intestinimonas* | *Oscillospiraceae* | 0.00 (0.00-0.02) | 0.03 (0.01-0.06) | 0.015 |
| *Haemophilus* | *Pasteurellaceae* | 0.00 (0.00-0.10) | 0.00 (0.00-0.01) | 0.031 |

Genera with an abundance of < 1% and not significantly different between patient groups are not presented. SIBO: Small intestinal bacterial overgrowth.